Janux Therapeutics (JANX)
(Delayed Data from NSDQ)
$22.83 USD
+0.25 (1.11%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $22.67 -0.16 (-0.70%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
JANX 22.83 +0.25(1.11%)
Will JANX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for JANX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JANX
JANX Stock Hits Record High on Prostate Cancer Study Data
Janux Therapeutics (JANX) Moves 6.5% Higher: Will This Strength Last?
JANX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for JANX
Buy Rating for Janux Therapeutics Driven by Promising Pipeline and Strong Financial Position
Decoding Janux Therapeutics Inc (JANX): A Strategic SWOT Insight
Janux Therapeutics GAAP EPS of -$0.55
Janux Therapeutics reports Q2 EPS (55c), consensus (47c)
Janux Therapeutics Inc (JANX) Announces First Patient Dosed in Merck Collaboration | JANX stock news